Literature DB >> 30867626

Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?

Lisa M Glass1, Christine M Hunt1, Michael Fuchs1, Grace L Su1.   

Abstract

Improvement in NAFLD may lead to improvement of metabolic syndrome, cardiovascular disease, and malignancy and vice versa.

Entities:  

Year:  2019        PMID： 30867626      PMCID： PMC6411365     

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


  18 in total

Review 1.  Defining comprehensive models of care for NAFLD.

Authors:  Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-25       Impact factor: 46.802

2.  Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.

Authors:  Juan P Frías; Jill Maaske; Lisa Suchower; Lars Johansson; Paul D Hockings; Nayyar Iqbal; John P H Wilding
Journal:  Diabetes Obes Metab       Date:  2021-09-28       Impact factor: 6.408

Review 3.  Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand.

Authors:  Rajvi Gor; Nabeel A Siddiqui; Ransirini Wijeratne Fernando; Archana Sreekantan Nair; Janan Illango; Mushrin Malik; Pousette Hamid
Journal:  Cureus       Date:  2021-05-05

4.  Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.

Authors:  Rifaat Safadi; Marius Braun; Adi Francis; Yael Milgrom; Muhammad Massarwa; David Hakimian; Wadi Hazou; Assaf Issachar; Zivit Harpaz; Motti Farbstein; Inbal Itzhak; Naama Lev-Cohain; Avital Bareket-Samish; Michael H Silverman; Pnina Fishman
Journal:  Aliment Pharmacol Ther       Date:  2021-10-20       Impact factor: 9.524

5.  Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.

Authors:  John J Nestor; David Parkes; Michael Feigh; John J Suschak; M Scott Harris
Journal:  Sci Rep       Date:  2022-04-23       Impact factor: 4.996

Review 6.  Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.

Authors:  Giandomenico Bisaccia; Fabrizio Ricci; Cesare Mantini; Claudio Tana; Gian Luca Romani; Cosima Schiavone; Sabina Gallina
Journal:  SAGE Open Med       Date:  2020-06-20

7.  New Perspectives of S-Adenosylmethionine (SAMe) Applications to Attenuate Fatty Acid-Induced Steatosis and Oxidative Stress in Hepatic and Endothelial Cells.

Authors:  Laura Vergani; Francesca Baldini; Mohamad Khalil; Adriana Voci; Pietro Putignano; Niccolò Miraglia
Journal:  Molecules       Date:  2020-09-15       Impact factor: 4.411

8.  Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet.

Authors:  Victoria Svop Jensen; Christian Fledelius; Erik Max Wulff; Jens Lykkesfeldt; Henning Hvid
Journal:  Nutrients       Date:  2021-02-12       Impact factor: 5.717

9.  Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients.

Authors:  Manuela Abbate; Catalina M Mascaró; Sofía Montemayor; María Barbería-Latasa; Miguel Casares; Cristina Gómez; Escarlata Angullo-Martinez; Silvia Tejada; Itziar Abete; Maria Angeles Zulet; Antoni Sureda; J Alfredo Martínez; Josep A Tur
Journal:  Nutrients       Date:  2021-02-15       Impact factor: 5.717

10.  Based on network pharmacology method to discovered the targets and therapeutic mechanism of Paederia scandens against nonalcoholic fatty liver disease in chicken.

Authors:  Qiang Wu; Fan Yang; Huaqiao Tang
Journal:  Poult Sci       Date:  2020-10-20       Impact factor: 3.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.